Pharma BD Deal Intelligence
On June 1, 2026, Agios Pharmaceuticals entered an exclusive global license agreement with South Korea's Oscotec to develop and commercialize cevidoplenib, a next-generation oral SYK (spleen tyrosine kinase) inhibitor, with an initial focus on immune thrombocytopenia (ITP), a rare autoimmune bleeding disorder. Oscotec receives $25 million upfront and is eligible for up to $140 million in development and regulatory milestones across up to three indications in the U.S. and Europe, plus commercial milestones and tiered royalties ranging from high-single-digit to mid-teen percentages on net sales. Oscotec retains an option to commercialize cevidoplenib in South Korea following Phase 3 results.